Serum concentrations of pegylated interferon α-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon α-2b in a randomized phase III trial (EORTC 18991)

被引：0
|
作者：
Alexander M. M. Eggermont
Marna G. Bouwhuis
Wim H. Kruit
Alessandro Testori
Timo ten Hagen
Antoine Yver
Christine Xu
机构：
[1] Erasmus University Medical Center,Department of Surgical Oncology
[2] Daniel den Hoed Cancer Center,Department of Medical Oncology
[3] Erasmus University Medical Center,Melanoma/Sarcoma Unit
[4] Daniel den Hoed Cancer Center,undefined
[5] European Institute of Oncology,undefined
[6] Schering-Plough Research Institute,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2010年 / 65卷
关键词：
Peginterferon alfa-2b; Melanoma; Pharmacokinetics; Cytokines;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：671 / 677
页数：6
相关论文
共 50 条
  • [1] Serum concentrations of pegylated interferon α-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon α-2b in a randomized phase III trial (EORTC 18991)
    Eggermont, Alexander M. M.
    Bouwhuis, Marna G.
    Kruit, Wim H.
    Testori, Alessandro
    ten Hagen, Timo
    Yver, Antoine
    Xu, Christine
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (04) : 671 - 677
  • [2] Prognostic value of autoantibodies in melanoma stage III patients in the EORTC 18991 phase III randomized trial comparing adjuvant pegylated interferon α2b vs observation
    Bouwhuis, M. G.
    Suciu, S.
    Testori, A.
    Santinami, M.
    Kruit, W. H.
    Punt, C. J.
    Sales, F.
    Patel, P. M.
    Spatz, A.
    Eggermont, A. M. M.
    [J]. EJC SUPPLEMENTS, 2007, 5 (06): : 5 - 6
  • [3] Adjuvant therapy with pegylated interferon α-2b versus observation in resected stage III melanoma:: final results of EORTC 18991, a randomised phase 3 trial
    Eggermont, A. M. M.
    Suciu, S.
    Santinami, M.
    Testori, A.
    Kruit, W.
    Marsden, J.
    Punt, C. J. A.
    Sales, F.
    Gore, M.
    Mckie, R.
    Kusic, V.
    Dummer, R.
    Musat, E.
    Spatz, A.
    Keilholz, U.
    [J]. PIGMENT CELL & MELANOMA RESEARCH, 2008, 21 (02) : 290 - 290
  • [4] EORTC 18991:: long term adjuvant pegylated interferon-α2b (PEG-IFN) vs observation in resected stage III melanoma:: final results of a randomized phase 3 trial
    Eggermont, A. M. M.
    Suciu, S.
    Santinami, M.
    Kruit, W.
    Testori, A.
    Marsden, J.
    Punt, C. J. A.
    Hauschild, A.
    Gore, M.
    Keilholz, U.
    [J]. ARCHIVES OF DERMATOLOGICAL RESEARCH, 2007, 299 (5-6) : 298 - 299
  • [5] Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma
    Eggermont, Alexander M. M.
    Suciu, Stefan
    Testori, Alessandro
    Santinami, Mario
    Kruit, Wim H. J.
    Marsden, Jeremy
    Punt, Cornelis J. A.
    Sales, Francois
    Dummer, Reinhard
    Robert, Caroline
    Schadendorf, Dirk
    Patel, Poulam M.
    de Schaetzen, Gaetan
    Spatz, Alan
    Keilholz, Ulrich
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (31) : 3810 - 3818
  • [6] Adjuvant pegylated interferon α-2b therapy for melanoma
    Schilling, Bastian
    Vaubel, Julia
    Schadendorf, Dirk
    [J]. ONCOLOGY LETTERS, 2010, 1 (02) : 237 - 241
  • [7] Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma:: final results of EORTC 18991, a randomised phase III trial
    Eggermont, Alexander M. M.
    Suciu, Stefan
    Santinami, Mario
    Testori, Alessandro
    Kruit, Wim H. J.
    Marsden, Jeremy
    Punt, Cornelis J. A.
    Sales, Francois
    Gore, Martin
    MacKie, Rona
    Kusic, Zvonko
    Dummer, Reinhard
    Hauschild, Axel
    Musat, Elena
    Spatz, Alain
    Keilholz, Ulrich
    [J]. LANCET, 2008, 372 (9633): : 117 - 126
  • [8] EORTC 18991: Long-term adjuvant pegylated interferon-alpha2b (PEG-IFN) compared to observation in resected stage III melanoma, final results of a randomized phase III trial
    Eggermont, A. M.
    Suciu, S.
    Santinami, M.
    Kruit, W.
    Testori, A.
    Marsden, J.
    Punt, C.
    Hauschild, A.
    Gore, M.
    Keilholz, U.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Adjuvant use of interferon α2b is not justified in patients with stage IIb/III melanoma
    Bajetta, Emilio
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (01): : 4 - 5
  • [10] Adjuvant use of interferon α2b is not justified in patients with stage IIb/III melanoma
    Emilio Bajetta
    [J]. Nature Clinical Practice Oncology, 2008, 5 : 4 - 5
12345